(Press-News.org) The first typhoon of the northern hemisphere 2012 typhoon season is headed for landfall in Vietnam. NASA's Aqua and TRMM satellites have been providing forecasters with valuable data on Typhoon Pakhar, that includes rainfall rates, cloud extent and temperature.
The Tropical Rainfall Measuring Mission (TRMM) satellite flew almost directly over Pakhar when it was a newly formed tropical storm in the South China Sea on March 29, 2012 at 1122 UTC/4:22 p.m. Asia local time (or 7:22 a.m. EDT). The intensifying storm had wind speeds of about 45 knots (~52 mph/~83 kph) and was moving toward the west-northwest when viewed by this TRMM pass. A rainfall analysis used data from TRMM's Microwave Imager and Precipitation Radar (PR) instruments. It showed that moderate to heavy rainfall of about 35 mm/hr (~1.4 inches) was located in an area around Pakhar's southwestern side.
"TRMM's PR was used to create a 3-D image of Pakhar's structure and showed that some of the storms were reaching heights of about 13 kilometers (~8 miles) above the ocean surface," Hal Pierce of the TRMM satellite team at NASA's Goddard Space Flight Center in Greenbelt, Md. where the images were created.
The Moderate Resolution Imaging Spectroradiometer (MODIS) instrument on NASA's Terra satellite captured a true-color image of Typhoon Pakhar on March 30, 2012 at 03:20 UTC/10:20 a.m. Asia local time (March 29 at 11:20 p.m. EDT) moving through the South China Sea toward Vietnam. Bands of thunderstorms are tightly wrapped around the center of Pakhar's center, and there may be an eye forming, but it is covered by dense overcast in MODIS visible imagery.
On March 30 at 0900 UTC (5 a.m. EDT) Pakhar's maximum sustained winds were at Typhoon strength, near 65 knots (~75 mph/120.4 kph). Pakhar is expected to intensify to 80 knots (90 mph/148 kph). Tropical-storm-force winds are occurring about 90 nautical miles (166.7 km) out from the center. Pakhar was located near 9.7 North and 111.0 East, about 260 nautical miles (481.5 km) east-southeast of Ho Chi Minh, Vietnam. Pakhar continues to move slowly at 3 knots (3.4 mph/5.5 kph), which will allow more time for the typhoon to build up strength in the warm waters of the South China Sea.
As Pakhar continues to intensify while moving slowly west towards Vietnam, forecasters at the Joint Typhoon Warning Center expect the storm to peak near 80 knots (90 mph/148 kph) before landfall. Landfall is forecast to occur near Phan Thiet, Vietnam around 1 a.m. Asia/Ho Chi Minh local time on Sunday, April 1 (1800 UTC / 2 p.m. EDT on Saturday, March 31).
For updates from the National Hydro-meteorological service in English or Vietnamese, visit: http://www.nchmf.gov.vn/web/en-US/104/102/12017/Default.aspx; and for a map of warning areas, visit: http://www.nchmf.gov.vn/web/en-US/43/Default.aspx.
Conditions continue to deteriorate in Vietnam as Pakhar moves toward the coast. On March 30, 2012 at 10:26 a.m. EDT (1426 UTC), Phan Theit, Vietnam was experiencing light rain and light easterly winds of 4 mph (6.4 kph).
Typhoon-force winds, heavy rainfall, and very rough coastal conditions are expected as Pakhar nears the coast later today, Saturday and Sunday. After landfall, Pakhar is forecast to move inland and dissipate quickly.
INFORMATION:
NASA sees Typhoon Pakhar headed for Vietnam landfall
2012-04-02
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Images capture split personality of dense suspensions
2012-04-02
Stir lots of small particles into water, and the resulting thick mixture appears highly viscous. When this dense suspension slips through a nozzle and forms a droplet, however, its behavior momentarily reveals a decidedly non-viscous side. University of Chicago physicists recorded this surprising behavior in laboratory experiments using high-speed photography that can capture action taking place in one hundred-thousandths of a second or less.
UChicago graduate student Marc Miskin and Heinrich Jaeger, the William J. Friedman and Alicia Townsend Friedman Professor in Physics, ...
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
2012-04-02
CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration-resistant prostate cancer (CRPC)," abstract ...
Early clinical data show galeterone safe, effective against prostate cancer
2012-04-02
CHICAGO — Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand ...
Metformin appeared to slow prostate cancer growth
2012-04-02
CHICAGO — The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.
Anthony M. Joshua, M.B.B.S., Ph.D., staff medical oncologist at the Princess Margaret Hospital, University Health Network in Toronto, Ontario, Canada, presented the data at the AACR Annual Meeting 2012, held here March 31 - April 4.
Metformin is the most commonly prescribed medication for diabetes. Prior laboratory research has suggested that metformin may ...
Biomarker identified in relation to drug response in refractory urothelial cancer
2012-04-02
CHICAGO — The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.
"Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea Necchi, M.D., faculty member in the department of medicine at Fondazione ...
Towards TB elimination: ECDC and ERS introduce new guidelines on tuberculosis care in Europe
2012-04-02
Today, the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC) publish their jointly developed European Union Standards for Tuberculosis Care (ESTC). The 21 patient-centred standards aim to guide clinicians and public health workers to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe – with nearly 74,000 reported TB cases in the EU/EEA in 2010 clearly showing that TB remains a public health challenge across the region.
The new EU-specific guidelines were developed by a panel of 30 experts ...
Oxygen in tumors predicts prostate cancer recurrence
2012-04-02
TORONTO -- Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy.
The clinical research, led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN) is published online today in Clinical Cancer Research, a journal of the American Association for Cancer Research (doi: 10.1158/1078-0432.CCR-11-2711).
"We've not only shown that men do worse if they have low oxygen levels (hypoxia) in their prostate cancer, but ...
2 targeted therapies act against Ewing's sarcoma tumors
2012-04-02
CHICAGO - A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.
Five of 17 Ewing's sarcoma patients responded to the combination, with two achieving complete responses, one for 27 weeks. The researchers noted that the ability to manage patients' treatment-related side effects is vital to maintaining the therapy and slowing disease progression. ...
Commonly used diabetes drug may help to prevent primary liver cancer
2012-04-02
Baltimore, MD – March 31, 2012. Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research. Primary liver cancer, or hepatocellular carcinoma, is an often-deadly form of cancer that is on the rise worldwide and is the fastest-growing cause of cancer-related deaths among American men.
Patients with Type II diabetes have a two- to three-fold increased relative risk of developing primary ...
Transforming scar tissue into beating hearts: The next instalment
2012-04-02
London -- The latest research developments to reprogram scar tissue resulting from myocardial infarction (MI) into viable heart muscle cells, were presented at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held 30 March to 1 April at the South Kensington Campus of Imperial College in London.
In a keynote lecture Dr Deepak Srivastava outlined his approach that has been described as a "game changer" with the potential to revolutionise treatment of MI. For the first time at the FCVB meeting, Srivastava presented the results of his latest studies using ...